









Markets
/
Stocks
/
nasdaq-huma
/

Humacyte Inc

HUMA

0.938USD

+0.052+5.88%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

149.04MMarket Cap

LossP/E TTM



Humacyte Inc

0.938

+0.052+5.88%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Humacyte Inc

Currency: USD Updated: 2026-02-06

Key Insights

Humacyte Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 140 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.71.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Humacyte Inc's Score

Industry at a Glance

Industry Ranking

140 / 392

Overall Ranking

285 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Humacyte Inc Highlights

StrengthsRisks

Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -3.64, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 48.29M shares, decreasing 41.55% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 11.78K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.67.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

7.714

Target Price

+770.49%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Humacyte Inc is 6.87, ranking 194 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.87

Change



Financials

5.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.55

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.12

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Humacyte Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Humacyte Inc is 6.68, ranking 238 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.64, which is -57.05% below the recent high of -1.56 and -669.76% above the recent low of -27.99.

Score

Industry at a Glance

Previous score

6.68

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 140/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Humacyte Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 3.50, with a high of 25.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

7.714

Target Price

+770.49%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Humacyte Inc

HUMA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Humacyte Inc is 5.48, ranking 315 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.15 and the support level at 0.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.27

Change

0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.016

Sell

RSI(14)

40.431

Neutral

STOCH(KDJ)(9,3,3)

22.235

Neutral

ATR(14)

0.081

Low Volatility

CCI(14)

-142.168

Sell

Williams %R

78.407

Sell

TRIX(12,20)

-0.567

Sell

StochRSI(14)

58.865

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.960

Sell

MA10

0.988

Sell

MA20

1.040

Sell

MA50

1.121

Sell

MA100

1.356

Sell

MA200

1.698

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Humacyte Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 25.02%, representing a quarter-over-quarter decrease of 14.32%. The largest institutional shareholder is The Vanguard, holding a total of 8.42M shares, representing 4.36% of shares outstanding, with 2.89% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fresenius SE & Co KGaA

18.31M

BlackRock Institutional Trust Company, N.A.

9.05M

-0.35%

Yushvaev (Gavril Abramovich)

8.94M

The Vanguard Group, Inc.

Star Investors

7.52M

+7.44%

Geode Capital Management, L.L.C.

3.10M

+5.01%

UBS Financial Services, Inc.

1.49M

-23.38%

State Street Investment Management (US)

2.41M

-45.16%

Ayabudge LLC

2.24M

+29.47%

Morgan Stanley & Co. LLC

2.04M

+54.57%

Woodline Partners LP

2.00M

+0.03%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Humacyte Inc is 3.56, ranking 136 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.93. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Humacyte Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.